标题:Hyper-progressive disease in a patient with advanced non-small cell lung cancer on immune checkpoint inhibitor therapy: A case report and literature review
作者:Zhang, Dongxiao; Zhang, Yan; Huang, Yong; Kong, Li; Yu, Jinming
作者机构:[Zhang, Dongxiao] Shandong Univ, Sch Med, Jinan, Shandong, Peoples R China.; [Zhang, Dongxiao; Zhang, Yan; Kong, Li; Yu, Jinming] Shandong Univ, Dep 更多
通讯作者:Yu, JM
通讯作者地址:[Yu, JM]Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jiyan Rd 440, Jinan 250117, Shandong, Peoples R China.
来源:LUNG CANCER
出版年:2020
卷:139
页码:18-21
DOI:10.1016/j.lungcan.2019.10.026
关键词:Hyper-progressive disease; Checkpoint inhibitor; Immunotherapy;; Non-small-cell lung cancer
摘要:Objectives: While immune checkpoint inhibitor (ICI) therapy has excellent efficacy in treating multiple cancers, some patients experience accelerated disease progression, defined as hyper-progressive disease (HPD). However, the characteristics of HPD, especially in patients with non-small-cell lung cancer (NSCLC), remain to be elucidated.; Materials and Methods: We report about an advanced NSCLC patient with striking disease progression, defined as HPD by existing standards, after the administration of pembrolizumab. We also reviewed related studies to discuss the definition, relative factors, and prognosis of HPD.; Results and Conclusion: This case of NSCLC with HPD had a series of characteristics not widely described in HPD cases previously reported, suggesting the potential complexity of this phenomenon and the necessity to study its characteristics and to more closely monitor patients who are administered ICIs.
收录类别:SCOPUS;SCIE
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85074359173&doi=10.1016%2fj.lungcan.2019.10.026&partnerID=40&md5=34bef9b202f7242740aa945dddb23fe6
TOP